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Background and objective: The Global initiative for chronic Obstructive Lung Disease 
(GOLD) Committee has proposed a chronic obstructive pulmonary disease (COPD) assessment 
framework focused on symptoms and on exacerbation risk. This study will evaluate a symptom 
and exacerbation risk-based treatment strategy based on GOLD in a real-world setting in Japan. 
Optimal management of COPD will be determined by assessing symptoms using the COPD 
Assessment Test (CAT) and by assessing the frequency of exacerbations.
Methods: This study (ClinicalTrials.gov identifier: NCT01762800) is a 24-week, multicenter, 
randomized, double-blind, double-dummy, parallel-group study. It aims to recruit 400 patients 
with moderate-to-severe COPD. Patients will be randomized to receive treatment with either 
salmeterol/fluticasone propionate (SFC) 50/250 µg twice daily or with tiotropium bromide 18 µg 
once daily. Optimal management of patients will be assessed at four-weekly intervals and, if 
patients remain symptomatic, as measured using the CAT, or experience an exacerbation, they 
have the option to step up to treatment with both drugs, ie, SFC twice daily and tiotropium once 
daily (TRIPLE therapy). The primary endpoint of the study will be the proportion of patients 
who are able to remain on the randomized therapy.
Results: No data are available. This paper summarizes the methodology of the study in advance 
of the study starting.
Conclusion: The results of this study will help physicians to understand whether TRIPLE 
therapy is more effective than either treatment strategy alone in controlling symptoms and exac-
erbations in patients with moderate-to-severe COPD. It will also help physicians to understand 
the GOLD recommendation work in Japan.
Keywords: COPD, GOLD, symptom, exacerbation risk, TRIPLE therapy
Introduction
Chronic obstructive pulmonary disease (COPD) is a common chronic inflammatory 
disease characterized by persistent airflow limitation, which is both preventable and 
treatable.1 The burden of COPD is considerable and increasing.2,3
The severity of COPD is influenced by exacerbations and comorbidities.4 
 Spirometry has remained the standard method for confirming a clinical diagnosis of 
COPD and for assessing COPD severity,5 but it is now accepted that forced expiratory 
volume in 1 second (FEV
1
) is an inadequate marker of the severity of breathlessness, 
exercise limitation, and health status impairment,1,4 although it remains important in 
the confirmation of a clinical diagnosis of COPD.
The Global initiative for chronic Obstructive Lung Disease (GOLD) strategy 
document, updated in 2011 and 2013, has proposed a new, multidimensional approach 
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to assess patients with COPD. It recommends that COPD 
management and treatment should consider both disease 
impact, determined by assessment of symptoms and activity 
limitation, and future risk of exacerbations, determined from 
airflow limitation or exacerbation history.5,6 This combined 
assessment of COPD results in the grouping of patients 
into one of four categories: (A) low risk, fewer symptoms; 
(B) low risk, more symptoms; (C) high risk, fewer symptoms; 
(D) high risk, more symptoms.
For assessing symptoms, GOLD advises utilizing either 
the COPD Assessment Test (CAT) or the modified Medical 
Research Council (mMRC) dyspnea scale. The CAT is a 
simple tool for quantifying the symptoms and impacts of 
COPD7,8 that has been shown to distinguish between different 
severities of COPD, is highly correlated with the St George’s 
Respiratory Questionnaire (SGRQ)7 and has been validated 
in Japan.9
In Japan, the name recognition of COPD is low, and 
the majority of these patients have not been diagnosed or 
appropriately treated.10 The prevalence of COPD is also 
underestimated in Japan.11,12 These findings highlighted 
the urgent need for improvements in COPD diagnosis and 
management in general practice. Most diagnosed patients 
are treated with bronchodilators such as long-acting β
2
 ago-
nists (LABAs) or long-acting antimuscarinics (LAMAs) as 
monotherapy, and remain symptomatic.13 It has now been 
recognized that monotherapy may not enable many patients 
to achieve the goals of pharmacologic therapy for COPD, 
namely to control symptoms, improve health status, and 
reduce the frequency of exacerbations.1 Guidelines on COPD 
management recommend the combined use of long-acting 
bronchodilators and inhaled corticosteroids (ICS) to optimize 
outcomes, especially exacerbations, in patients with COPD 
that is inadequately controlled with monotherapy.1 It has 
been demonstrated that, in some patients, TRIPLE therapy, in 
which an anticholinergic is added to an ICS and LABA, has 
been associated with greater improvements in lung function 
and quality of life and with reduced rates of hospitalization 
compared with anticholinergic therapy alone.13–17
The aim of this innovative study is to assess the control of 
COPD using a symptom and exacerbation risk-based treatment 
strategy according to GOLD 2011. This study has been named 
the “COPD Symptom-based Management and to Optimise treat-
ment Strategy in Japan” (COSMOS-J) and has been designed to 
reflect clinical practice in Japan. Unlike a  “traditional” random-
ized controlled trial, treatment in this study is flexible as it tries 
to reflect clinical practice. This will demonstrate whether the 
treatment approach outlined in the GOLD strategy document 
can be used to improve the current management of COPD in 
Japan. New Japanese guidelines are also anticipated in 2013, 
which may improve clinical practice. Optimal management of 
COPD, determined by assessing symptoms using CAT and by 
assessing the frequency of exacerbations, will be assessed in 
patients who have been randomized to receive treatment with 
either salmeterol/fluticasone propionate combination (SFC) 
or with tiotropium bromide. If optimal management is not 
achieved on one of these two treatments and patients remain 
symptomatic or experience an exacerbation, patients have the 
option to step up to treatment with both drugs, ie, TRIPLE 
therapy. This paper summarizes the methodology of the study 
in advance of the publication of the results.
Methods
study design
This study is a 24-week, multicenter, randomized, parallel-
group study. Initial study treatments will be double-blind and 
double-dummy. This study will include a switch treatment 
strategy for those not adequately controlled on randomized 
medication. The study aims to recruit 400 patients with 
moderate-to-severe COPD; 200 patients per treatment arm. 
After a 4-week run-in period, during which patients will 
remain on their usual treatment for COPD, patients will be 
randomized to receive SFC (Adoair™, GlaxoSmithKline 
KK, Tokyo, Japan) 50/250 µg twice daily delivered via 
the Diskus™ (GlaxoSmithKline KK) inhalation device, or 
tiotropium bromide (Spiriva™, Boehringer Ingelheim Pharma 
GmbH and Co, KG Ingelheim, Germany) 18 µg delivered 
once daily via the Handihaler™ inhalation device (Boeh-
ringer Ingelheim Pharma GmbH and Co), for 24 weeks. SFC 
50/250 µg is the licensed dose in Japan. Within the double-
dummy study design (Figure 1), patients in both groups also 
receive placebo medication via a matched-placebo inhalation 
device. Subjects treated with TRIPLE therapy will receive 
open-label medication. During the run-in, regular treatment 
with any COPD medications is allowed, except for systemic 
corticosteroids and antibiotics used for COPD exacerbation. 
The use of other COPD medication such as antitussives, 
expectorants, and mucolytics is permitted throughout the 
study at the investigator’s discretion. Salbutamol for use on 
an as required basis for relief medication, short-term oxygen 
therapy for treatment of COPD exacerbation, and short-term 
courses of systemic steroids and/or antibiotics for a COPD 
exacerbation or adverse event (AE) will also be allowed. No 
ICS, LABAs, leukotriene antagonists, phosphodiesterase 
(PDE)-4 inhibitors, anticholinergics, and regular or long-
term oxygen therapy ($12 hours oxygen use per day) will be 
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allowed, except for randomized study  treatment. If a  moderate 
or severe exacerbation occurs more than once or the CAT 
score is increased by more than four points after switching 
to TRIPLE therapy, regular use of COPD medications other 
than systemic steroids, ICS, β
2
-agonists, and anticholinergic 
agents is permitted.
study protocol
Post-randomization, patients will be reviewed every 4 weeks 
to assess their symptom level and the occurrence of any 
exacerbations (Figure 1). This will be done using the CAT, 
and asking whether there have been any noticeable changes 
since the last visit and whether an exacerbation has occurred. 
FEV
1
 and forced vital capacity (FVC) will also be measured 
at each visit.
Based on the CAT score and presence or absence of exac-
erbations, at each visit the investigator will ask the subject 
questions in accordance with the guidance for optimization 
of COPD treatment (Table 1). Randomized treatment will be 
switched to TRIPLE therapy if necessary, having taken the 
subject’s answers and his/her medical course into consider-
ation and having obtained their agreement. The necessity of 
switching treatments to TRIPLE therapy should be assessed 
at unscheduled visits, if any, as well as at scheduled visits.
At the first scheduled visit after switching to TRIPLE 
therapy, TRIPLE therapy should be continued to the next 
scheduled visit even if there is no improvement in symptoms, 
since benefits may take more than 1 month to develop.
At the second scheduled visit after switching to TRIPLE 
therapy, if COPD symptoms are not improved, or if the sub-
ject is unsatisfied with the study treatment in spite of switch-
ing to TRIPLE therapy, or they have developed side effects 
due to the added treatment, the investigator should consider 
changing treatments back to the double-blinded randomized 
medication. Following a switch back from TRIPLE to the 
randomized treatment, the physician can return to TRIPLE, 
if the patient’s COPD symptoms justify it or if the subject is 
unsatisfied with the randomized treatment.
In cases when patients are changed to TRIPLE because of 
a moderate or severe COPD exacerbation, TRIPLE therapy 
should be continued throughout the course of the study. The 
investigator should consider adding other COPD medications 
or suitable treatment if an exacerbation has occurred more than 
once during the study or the CAT score has increased more 
than four points despite switching to TRIPLE therapy.
Patient participation
Patients will be aged 40–80 years with an established 
clinical history of COPD as def ined by the GOLD 
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Figure 1 study design.
Abbreviations: sFC, salmeterol/fluticasone propionate; Tio, tiotropium bromide; TRIPLE, SFC twice daily and Tio once daily.
Table 1 guidance for COPD control on randomized therapy
CAT/exacerbation Guidance
CaT ,10 “Your score suggests you are doing 
well. Are you satisfied with your current 
treatment?”
10# CaT #15 “Your score suggests your chest 
trouble is causing you some problems 
because [...]. Are you satisfied with your 
current treatment?”
CaT .15 “Your score clearly suggests your chest 
problem is having a big effect on you. We 
have an option to increase treatment. Do 
you want to try it?”
Moderate or severe  
COPD exacerbation
switch to TrIPle therapy
Abbreviations: CAT, COPD Assessment Test; SFC, salmeterol/fluticasone propionate; 
Tio, tiotropium bromide; TrIPle, sFC twice daily and Tio once daily; COPD, chronic 
obstructive pulmonary disease.
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guidelines,4 with a current or former smoking history 
of $10 pack years, a post-bronchodilator FEV
1
 of $30% 
to #80% of the predicted normal value, a post-broncho-
dilator FEV
1
/FVC ratio of ,70%, and a grade of $1 on 
the mMRC scale.18 Exclusion criteria for entry to the study 
include a medical diagnosis of predominant asthma or a 
respiratory disorder other than COPD that might interfere 
with the study, lung transplantation and/or lung volume 
reduction, and a requirement for regular or long-term 
oxygen therapy. Patients on long-term oxygen therapy 
would be unlikely to be able to complete the study, with 
long-term oxygen therapy defined as $12 hours of oxygen 
a day. Other exclusion criteria include a plan to start or 
change to a pulmonary rehabilitation program during the 
study period, regular treatment with oral, parenteral, or 
depot corticosteroids, a chest X-ray indicating a diagnosis 
other than COPD, or any other serious, uncontrolled dis-
ease likely to interfere with the study. Patients who have 
received any other investigational drug within 4 weeks of 
the study are also excluded from the study. As with other 
anticholinergic drugs, patients with a medical diagnosis of 
narrow-angle glaucoma, prostatic hyperplasia, or bladder 
neck obstruction should only be entered at the investiga-
tor’s discretion.
Randomization is remote and concealed from centers 
and uses a 1:1 allocation ratio. The primary population for 
analysis is the modified intent-to-treat (m-ITT) population, 
which will include all patients randomized to treatment who 
have received at least one dose of trial medication.
The study is being conducted in accordance with the 
International Conference on Harmonisation Good Clinical 
Practice and the 2008 version of the Declaration of Helsinki. 
All patients must provide a written informed consent form 
prior to participation. The ethics and review boards of all 
participating institutions have approved the protocol (GSK 
study code: SCO116717; NCT01762800).19
Efficacy assessments
The primary efficacy endpoint is the proportion of patients 
who are able to remain on the randomized therapy. Secondary 
and other efficacy endpoints are listed in Table 2.
exacerbations
A COPD exacerbation is defined as a sustained worsening of 
COPD symptoms beyond normal day-to-day variations. The 
investigator will record all COPD exacerbations throughout 
the study period in accordance with the classification of 
exacerbation severity.
•	 An exacerbation will be classified as a mild exacerbation 
if treated with relief medication only.
•	 An exacerbation will be classif ied as a moderate 
 exacerbation if treated with systemic corticosteroids and/
or antibiotics.
•	 An exacerbation will be classified severe exacerba-
tion if hospitalization is required for treatment of the 
exacerbation.
In this study, both reported and unreported COPD 
exacerbations will be assessed using the EXAcerba-
tions of Chronic Pulmonary Disease Tool (EXACT).20–22 
 Unreported exacerbations will be determined from 
symptoms recorded by patients on daily record cards. 
After the screening visit, subjects will record their respi-
ratory symptoms and physical condition every day. Use 
of relief  medication will also be recorded on the daily 
record cards.
safety assessment
Safety will be measured by recording any AEs and COPD 
exacerbations.
statistical analysis
Assuming a 10% to 60% switch rate from the initial treat-
ment group, a 15% difference will be detectable with 86% 
to 99% power by log-rank test using the planned sample size 
of 400 subjects.
For the primary comparison of interest, the proportion 
of patients remaining on randomized therapy (=1-TRIPLE 
switch rate) and time to switch to TRIPLE will be estimated 
Table 2 secondary endpoints
Proportion of patients who switched to TrIPle therapy
Proportion of patients controlled by TrIPle therapy
Proportion of patients controlled by randomized therapy plus TrIPle 
therapy
Time to switching to TrIPle therapy
Time to first exacerbation
Proportion of exacerbation confirmed by EXACT
Proportion of exacerbations detected by EXACT not diagnosed
CaT score change
Change in FeV1
Use of relief medication
Proportion of patients who decreased treatment from TrIPle therapy
Proportion of patients who required additional treatment to TrIPle 
therapy
Proportion of patients who dropped out
Patient’s judgment of treatment efficacy
Physician’s judgment of treatment efficacy
Abbreviations: CAT, COPD Assessment Test; EXACT, EXAcerbations of 
Chronic Pulmonary Disease Tool; FeV1, forced expiratory volume in 1 second; sFC, 
salmeterol/fluticasone propionate; TRIPLE, SFC twice daily and tiotropium once daily; 
COPD, chronic obstructive pulmonary disease.
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by Cox’s proportional hazard model. A Kaplan–Meier plot 
will be prepared.
Descriptive statistics of FEV
1
 and CAT scores will be 
presented. AEs will be coded according to the Medical 
Dictionary for Regulatory Activities (MedDRA) and sum-
marized by body systems and preferred terms. Serious AEs, 
drug-related AEs, and events leading to withdrawal will also 
be summarized.
The primary analysis population will be the m-ITT, which 
will consist of randomized subjects who received at least a 
single dose of the investigational product.
Discussion
It is now recognized that the treatment of COPD should 
involve more than improving lung function since the impact 
of lung function impairment varies greatly between individual 
patients. Exacerbations and symptoms also have a significant 
impact on the health status of these patients.4,23–25 As a result, 
the GOLD 2011 Strategy Document, updated in 2013, has 
produced a treatment algorithm based on the assessment of 
symptoms and exacerbations with the aim of enabling more 
effective treatment of COPD.5,6 However, this strategy has 
not been tested in a clinical trial, and it is also not clear what 
proportion and what type of patients can be managed on a 
single therapy and which should receive multiple therapies. 
This study will attempt to clarify aspects of this and to deter-
mine whether this strategy can improve the management of 
COPD, particularly in a Japanese setting.
This strategy cannot easily be tested in a usual randomized 
clinical trial design since this does not reflect real clinical 
practice (eg, withdrawal from a study often occurs when 
the study treatment to which the patient is randomized in a 
blinded manner is judged to be insufficiently effective). More-
over, subject withdrawals from randomized clinical trials are 
usually the sickest patients who, in real clinical practice, are 
those who need the most help.26 A further complication of 
withdrawals in randomized clinical trials is that this risks a 
significant study bias.27 It is known that long-term trials in 
COPD present difficult problems of design and statistical 
analysis.27
In order to test the GOLD strategy, a new type of study 
design has therefore been introduced. It starts like a usual 
type of clinical trial with two randomized, blinded arms 
of appropriate COPD treatments. At each visit, the inves-
tigator then assesses the effectiveness of the treatment by 
assessing symptoms (checking the CAT score, asking the 
subject how they feel about their treatment using formal 
study-designed questions, and checking for exacerbation 
events). The Japanese version of the CAT has been shown 
to have high reliability and validity for precise assessment 
of the health status of Japanese patients with COPD.9 It 
is important to note that lung function measurements are 
not used as criteria for treatment change in this study. The 
primary efficacy endpoint is the proportion of patients who 
are controlled and able to remain on the randomized therapy. 
At each assessment point, if the treatment is judged to be 
satisfactory, the patient’s treatment remains unchanged. 
However, if the treatment is not felt to be effective, instead 
of the patient having to withdraw or continue on the same 
therapy but under-treated in terms of their symptoms, the 
investigator can increase the treatment. This process will 
occur at each visit and, depending on treatment response, 
there are options in this study design to maintain, increase, or 
reduce the treatment as appropriate, thus mimicking clinical 
practice as far as possible.
TRIPLE therapy, which adds an LAMA to ICS/LABA 
combinations, has been associated with greater improve-
ments in lung function and quality of life and reduced rates 
of hospitalization compared with anticholinergic therapy 
alone.13–17 While the efficacy and tolerability of TRIPLE 
therapy have been evaluated in clinical trials, the effect on 
COPD outcomes of TRIPLE therapy relative to LAMA and 
SFC alone has not been assessed outside the confines of a 
controlled clinical trial.
The strengths of this study design are that a level of treat-
ment flexibility is allowed, which better reflects real clinical 
practice than a randomized clinical trial and this should also 
ensure that the sicker patients are not lost from the study. This 
makes it possible to test the hypothesis behind the GOLD 
2011 treatment strategy. The principal weakness in the study 
design is that when treatment is increased, the blinding will 
be lost. However, there has to be a compromise to achieve 
the study objectives and this is probably the best solution. 
An additional limitation is that the only valid options for 
treatment are an LAMA or combined LABA/ICS therapy, 
and that the next obvious step is TRIPLE. However, adding 
an LABA to an LAMA (without an ICS) may be a valid 
option for patients not controlled with an LAMA alone in 
terms of symptoms.
If this study design is successful, the methodology 
can be used for future studies with new therapies and may 
complement the standard fixed treatment approach of 
randomized clinical trials for drug registration purposes. 
The results of this study will also help physicians to under-
stand if TRIPLE therapy is more effective in controlling 
symptoms and exacerbations in patients with moderate 
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to severe COPD when compared with either treatment 
strategy alone. This study will also help physicians to 
understand the GOLD  recommendation work in Japan 
when communicating with their patients and with using 
the available medications.
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